Navigation Links
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Date:11/9/2008

NEW ORLEANS, Nov. 9 /PRNewswire-FirstCall/ -- New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

Results also showed that for patients in the trial taking rosuvastatin:

-- the combined risk of heart attack, stroke or CV death was reduced by

nearly half (47%, p<0.001).

-- risk of heart attack was cut by more than half (54%, p<0.001).

-- risk of stroke was cut by nearly half (48%, p=0.002).

-- total mortality was significantly reduced by 20% (p=0.02).

These results were accompanied by a median LDL-C reduction of 50% (p<0.001) resulting in an on-treatment median LDL-C of 55 mg/dL.

On the basis of the data, if the results are projected over a period of 5 years, 25 patients would need to be treated to prevent one major cardiovascular event (NNT=25).

The JUPITER results will be presented today at the American Heart Association Scientific Sessions and were simultaneously published online by the New England Journal of Medicine.

"These results provide new information about CRESTOR's effects on CV risk. The JUPITER trial confirmed that CRESTOR dramatically reduces LDL-C cholesterol levels and has now demonstrated a nearly 50% reduction in the risk of heart attack and stroke in a population of patients who had elevated hsCRP but low to normal cholesterol levels," said Howard Hutchinson, Chief Medical Officer for AstraZeneca. "As is appropriate, the medical community, regulators, and guideline committees will now carefully consider these data and any implications for treating patients."

As previously guid
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  eRelevance Corporation ( www.erelevancecorp.com ), a ... it has completed integration with Nextech, a popular ... and Dermatology practices. "Integration allows our ... practices using Nextech," stated Bob Fabbio , ... from the EMR we are able to automatically ...
(Date:8/21/2014)... Aug. 21, 2014  Publicis Groupe customer engagement ... Managing Partner and Healthcare Industry Group Leader, has been ... recognizes the most inspiring people in the life-sciences industry. ... research and development, marketing, technology, creativity, strategy and medicine. ... as a partner in its leading Rosetta Consulting practice. ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy ... new comic series designed to educate children about the most ... The Medikidz Explain Epilepsy comic series tells a ... is navigating middle school while living with epilepsy. ... Canadians, there is still so much misinformation and lack of ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... Oncology Group -, BRISBANE, Calif., May 28 ... its clinical trials program through the,initiation of an ... candidate,BSI-201. The trial will assess BSI-201, the first ... portfolio, for the treatment,of uterine carcinosarcoma or malignant ...
... FDA Approval Based on Updated Results Showing a 20% Reduction ... a 22% Improvement of Disease Free Survival at ... III Colon Cancer, Post Surgery -, BRIDGEWATER, N.J., May ... Drug Administration (FDA) approved,the supplemental new drug application (sNDA) to ...
Cached Medicine Technology:BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 2New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 2New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 3New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 4
(Date:8/22/2014)... Back-to-school time provides an opportunity for parents to develop ... an expert suggests. "Forget New Year,s resolutions; the ... the start of a new fitness and exercise program ... the University of the Sciences in Philadelphia, said in ... likely to build up, "it,s important for mom and ...
(Date:8/22/2014)... A national leader in home delivery of medical ... to grow. , Headquarters for the provider of sterile-use catheters ... at 8516 N.W. Expressway in Oklahoma City. , Rapid ... best places to work by OKCBiz magazine – demanded more ... in the past two years, and staff count grew 30 ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Menstrual leaks ... inventor from Sunrise, Fla., decided that there needed to ... Easy to use and producible in design variations, the ... caused by leaks, which avoids embarrassment and promotes peace ... conventional sanitary pads. , The original design was submitted ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Counseling may ... a large-scale review finds. Researchers analyzed 66 studies ... of whom were at high risk for drinking problems. ... session, while participants in the rest of the studies ... individual sessions. A counseling technique called motivational interviewing ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- College can be a ... of things they can do to make the most of ... time to adjust, explore, meet new people and learn to ... of student wellness and assessment at St. John,s University in ... "Not all learning takes place in the classroom. College is ...
Breaking Medicine News(10 mins):Health News:With Kids in School, Parents Can Work Out 2Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:College Prep 101 2
... Mo., Nov. 16 Mercy Medicare ADVANTAGE is the ... Excellent Rating by the Centers for Medicare and Medicaid Services. ... during the 2009 Consumer Assessment of Healthcare Providers and Systems ... produced by Centers for Medicare & Medicaid Services ranked each ...
... HARRISBURG, Pa., Nov. 16 The federal Centers for ... total of 1,686,100 doses of H1N1 vaccine to Pennsylvania ... , The vaccine has been distributed to 1,312 certified ... colleges and universities that agreed to target the groups ...
... , WEIFANG, China, ... ("Shengtai" or "the Company"),a leading manufacturer and distributor of high-quality, ... the first,quarter of fiscal 2010 ended September 30, 2009. , ... -- First quarter 2010 revenues totaled $23.13 million, ...
... diagnosis and monitoring of Alzheimer,s disease, scientists at the ... and accurate method for quantifying subtle, sub-regional brain volume ... be published the week of November 16 in the ... ( PNAS ). By applying the techniques to ...
... researchers say , MONDAY, Nov. 16 (HealthDay News) -- If ... be at significantly increased risk for stroke, heart disease and ... aged 50 and older, with no history of cardiovascular disease. ... vitamin D levels: normal (more than 30 nanograms per milliliter), ...
... , FORT LAUDERDALE, Fla., Nov. 16 Patriot Risk ... announced today that it has been awarded Case Management ... organization that establishes quality standards for the health care ... establish a process to assess, plan and implement case ...
Cached Medicine News:Health News:Mercy Health Plans Receives Five Star Excellent Rating 2Health News:Department of Health Updates H1N1 Vaccine Distribution Effort, Reminds At-Risk Residents of Upcoming Vaccination Clinics 2Health News:Department of Health Updates H1N1 Vaccine Distribution Effort, Reminds At-Risk Residents of Upcoming Vaccination Clinics 3Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Fiscal Year 2010 Financial Results 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Fiscal Year 2010 Financial Results 3Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Fiscal Year 2010 Financial Results 4Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Fiscal Year 2010 Financial Results 5Health News:Analyzing structural brain changes in Alzheimer's disease 2Health News:Low Vitamin D Levels Linked to Heart Disease 2Health News:Patriot Risk Services, Inc. Receives URAC Case Management Accreditation 2
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: